TAG:
cap
Misinterpreted Gene Test Shows Lab Got it Right
By Joseph Burns | From the Volume XXIV No. 17 – December 11, 2017 Issue
CEO SUMMARY: It’s almost a case of man bites dog. In malpractice cases involving genetic test results, labs are often assumed to be at fault. But in a lawsuit filed in Oregon, healthcare providers are alleged to have misinterpreted a genetic test. As a consequence, a patient underwent m…
Value of Miraca Falls By 92% from 2011 to 2017
By Joseph Burns | From the Volume XXIV No. 17 – December 11, 2017 Issue
CEO SUMMARY: Miraca Life Sciences amended its merger agreement with Avista Capital Partners after the lab lost value in the two months since the agreement was signed in September. Factors precipitating the revision were a significant decline in reimbursement rates, stiff competition from …
TOP 10 LAB STORIES OF 2017
By Robert Michel | From the Volume XXIV No. 17 – December 11, 2017 Issue
1. CMS Sticks by Decision to Deeply Cut Medicare Part B Lab Test Fees SHORT OF A MIRACLE, the clinical laboratory industry is less than three weeks from the single most financially-disruptive event of the past 30 years. On Jan. 1, the federal Centers for Medicare and Medicaid Service…
Top 10 Lab Stories of 2017 Dominated by Part B Cuts
By Robert Michel | From the Volume XXIV No. 17 – December 11, 2017 Issue
CEO SUMMARY: In hindsight, 2017 is likely to be remembered as a milestone year that launched several disruptive developments that will reshape the lab industry moving forward. For the clinical laboratory sector this year, CMS confirmed its intent to slash Part B clinical laboratory test price…
FDA Clears Waived CBC For Near-Patient Testing
By R. Lewis Dark | From the Volume XXIV No. 16 – November 20, 2017 Issue
CEO SUMMARY: Market clearance of the first-ever CLIA-waived analyzer for complete blood count and three-part differential tests could cut time-to-answer from days to mere minutes for one of the top 20 tests by volume performed at core laboratories. Developer Sysmex America, Inc., foresees…
CMS Publishes Final CLFS Rates, Labs Prepare to Cut Staff or Close
By Joseph Burns | From the Volume XXIV No. 16 – November 20, 2017 Issue
MEDICARE OFFICIALS PUBLISHED the final Part B Clinical Laboratory Fee Schedule for 2018 last Friday. Some changes clinical labs will welcome. The rates remain deeply flawed, however, and will cause many labs to lay off staff and others to close, experts said Saturday. How CMS set the rates remains p…
Surprisingly Low Price Paid for Miraca’s AP Lab Is a Warning
By Joseph Burns | From the Volume XXIV No. 16 – November 20, 2017 Issue
EVEN INTO THE MID 1980s, coal miners used canaries as an early-detection system for the presence of carbon monoxide and other toxic gases. In this way, canaries served as a sentinel species to save miners’ lives. Clinical laboratories and pathology groups don’t have a sentinel species to warn th…
Is the Worm Turning in Favor of Hospital Labs?
By R. Lewis Dark | From the Volume XXIV No. 16 – November 20, 2017 Issue
SINCE THE MID-1990S, HOSPITAL OUTREACH LABORATORY PROGRAMS have lost market share steadily to the nation’s biggest public lab companies. In these two decades, public lab companies traded deeply-discounted lab test prices to health insurers in exchange for exclusive network provider status. Then, a…
Tougher Times Ahead as Labs React to Fee Cuts
By Joseph Burns | From the Volume XXIV No. 16 – November 20, 2017 Issue
CEO SUMMARY: Just as Nero is reputed to have fiddled while Rome burned, officials at CMS seem to be doing their own fiddling as their planned deep price cuts to Medicare Part B lab tests could begin driving lab companies out of business. In recent weeks, the owners of two lab companies de…
November 20, 2017 Intelligence: Late Breaking Lab News
By R. Lewis Dark | From the Volume XXIV No. 16 – November 20, 2017 Issue
Last Friday, Roche announced an agreement to acquire Viewics, Inc., of Sunnyvale, Calif., in a transaction that, subject to regulatory clearance, is expected to close on Nov. 21. Viewics sells a middleware analytics solution to clinical labs. Terms of the sale were n…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized